Free tool
FAERS Monitor: Envarsus Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206406 or its brand name (Envarsus Xr, Tacrolimus). Reports on generic versions are filed under their own applications.
Reports
131,679
Serious
118,245
90% of reports
Hospitalization
52,492
Death reported
20,659
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use13,632
- drug ineffective9,158
- product use in unapproved indication6,247
- drug interaction5,771
- acute kidney injury5,731
- diarrhoea4,761
- transplant rejection4,365
- cytomegalovirus infection4,225
- pyrexia3,958
- covid-193,872
- toxicity to various agents3,789
- pneumonia3,755
- death3,688
- renal impairment3,039
- post transplant lymphoproliferative disorder3,003
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 169 |
| 2005 | 219 |
| 2006 | 259 |
| 2007 | 555 |
| 2008 | 951 |
| 2009 | 1,053 |
| 2010 | 1,201 |
| 2011 | 2,205 |
| 2012 | 2,459 |
| 2013 | 1,608 |
| 2014 | 2,523 |
| 2015 | 3,011 |
| 2016 | 4,273 |
| 2017 | 6,324 |
| 2018 | 9,468 |
| 2019 | 9,832 |
| 2020 | 11,792 |
| 2021 | 11,245 |
| 2022 | 11,517 |
| 2023 | 12,900 |
| 2024 | 14,007 |
| 2025 | 13,919 |
| 2026 | 10,189 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,922,480 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| post transplant lymphoproliferative disorderSignal | 3,003 | 228.1 | 215.8 | 278,744 |
| transplant rejectionSignal | 4,365 | 189.7 | 181.6 | 373,470 |
| cytomegalovirus infectionSignal | 4,225 | 54.1 | 52.3 | 164,325 |
| acute kidney injurySignal | 5,731 | 6.2 | 6.0 | 24,097 |
| drug interactionSignal | 5,771 | 6.0 | 5.8 | 23,299 |
| renal impairmentSignal | 3,039 | 6.0 | 5.7 | 12,128 |
| product use in unapproved indicationSignal | 6,247 | 4.1 | 4.0 | 14,465 |
| toxicity to various agentsSignal | 3,789 | 3.6 | 3.5 | 7,175 |
| covid-19Signal | 3,872 | 3.6 | 3.5 | 7,105 |
| off label useSignal | 13,632 | 2.5 | 2.5 | 12,721 |
| pneumonia | 3,755 | 1.9 | 1.8 | 1,505 |
| pyrexia | 3,958 | 1.8 | 1.8 | 1,515 |
| diarrhoea | 4,761 | 1.2 | 1.1 | 133 |
| drug ineffective | 9,158 | 1.1 | 1.1 | 107 |
| death | 3,688 | 0.7 | 0.7 | 566 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.